Presentation time: 27 Feb 2020 at 9.30
Presentation: 200227_Targovax_RAS_Summit
Vaccinating Against Mutant RAS – Results from TG01 Phase I/II Trial
• Results from 32-patient TG01 trial in resected pancreatic cancer
• Robust immune responses demonstrated against KRAS
• Overview of clinical and molecular outcomes